Analysts: Zimmer Biomet CEO’s departure long-needed
Zimmer Biomet pre-announced disappointing second-quarter results while also revealing that David Dvorak had stepped down as CEO, a move that some analysts feel was long needed.
Zimmer Biomet pre-announced disappointing second-quarter results while also revealing that David Dvorak had stepped down as CEO, a move that some analysts feel was long needed.
The shift from volume to value is no where more apparent than in the orthopedics specialty where vendors that once obsessed over titanium and steel are now focusing on services to manage the bundled payment era.
As the buzz around robotics grows, J&J 's DePuy Synthes is touting the clinical and economic evidence tied to its non-robotic knee platform to help hospitals navigate the bundled payments era, but will that sway them?
Zimmer Biomet just acquired a telerehab startup, RespondWell, to play in a different part of the bundle as it relates to the Comprehensive Care for Joint Replacement program for hip and knee replacements. Stryker is not interested in such technology.
The deal reflects Zimmer Biomet's interest in supporting value-based care through the company's Signature Solutions program to hospitals.
Zimmer Biomet wants to help hospitals use technology and other tools to maintain good patient outcomes and improve hospital efficiencies in a bid to stay relevant in the shift to value-based care.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
After dismissing robotics in orthopedics, Zimmer Biomet is jumping on the bandwagon.
Digital health business DocPlanner is aiming for world domination in the online physician appointment setting market.
The news this week that the same nerve cells that control our ability to smell can apparently be used to help paralyzed people walk is thrilling stuff. The process that led up to the surgery was years in the making. Here’s an overview. Doctors zeroed in on olfactory nerve cells in the first place because […]